Kingworld Medicines Group Limited

Equities

1110

KYG5268M1006

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:06 2024-04-30 am EDT 5-day change 1st Jan Change
0.55 HKD +1.85% Intraday chart for Kingworld Medicines Group Limited +10.00% -12.70%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Kingworld Medicines Posts 68% Jump in 2023 Profit MT
Kingworld Medicines Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024 CI
Kingworld Medicines Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Kingworld Medicine Expects Up to 75% Profit Jump in 2023; Shares Up 6% MT
Kingworld Medicines Group Limited Provides consolidated Earnings Guidance for the Year Ended 31 December 2023 CI
Kingworld Medicines Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Kingworld Medicines Subsidiary Buys Shares in Taiko Pharmaceutical MT
Kingworld Medicines Group Expects Up to 40% Rise in H1 Profit MT
Kingworld Medicines Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2023 CI
Kingworld Medicines Group Limited Approves Final Dividend for the Year Ended 31 December 2022 CI
Kingworld Medicines to Invest 832 Million Yen in Taiko Pharmaceutical MT
Kingworld Medicines to Grant 3.5 Million Awarded Shares Under 2019 Scheme MT
Kingworld Medicines Group Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2022, Payable on 30 June 2023 CI
Kingworld Medicines Group Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
KIngworld Medicines Group Acquires 60% Stake in Innopharm MT
Kingworld Medicines Completes Topping Out Process of Longde Health Industrial Park MT
Kingworld's H1 Profit Jumps MT
Kingworld Medicines Group Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Kingworld Medicines Group Forecasts Up To 25% Rise in H1 Net Profit MT
Kingworld Medicines Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2022 CI
Kingworld Medicines Group Limited Announces Final Cash Dividend for the Financial Year Ended 31 December 2021, Payable on 30 June 2022 CI
Kingworld Medicines Group Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 30 June 2022 CI
Kingworld Medicines Group Limited Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Kingworld Medicines Sees up to 160% Surge in 2021 Profit MT
Kingworld Medicines Group Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2021 CI
Chart Kingworld Medicines Group Limited
More charts
Kingworld Medicines Group Limited is an investment holding company principally engaged in the distribution and sales of pharmaceutical and healthcare products. The Company’s products include cough and phlegm relieving, gastrointestinal, vitamin, orthopedics, cardiovascular, influenza and others. The Company operates through two business segments. The Distribution Sales of Pharmaceutical and Healthcare Products segment is engaged in the distribution and sales of branded imported pharmaceutical and healthcare products primarily in Hong Kong and the People’s Republic of China (PRC). The Manufacturing and Sales of Electrotherapeutic and Physiotherapeutic Devices and General Medical Examination Devices segment is engaged in the manufacture and sales of electrotherapeutic and physiotherapeutic devices, as well as general medical examination devices in the PRC.
More about the company
  1. Stock Market
  2. Equities
  3. 1110 Stock
  4. News Kingworld Medicines Group Limited
  5. Kingworld Medicines to Invest 832 Million Yen in Taiko Pharmaceutical